A study to determine global impact of COVID-19 vaccines in terms of infections, hospitalizations, and risk of deaths

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 27 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ad26.COV2 S (Primary) ; Ad5-nCoV Tianjin CanSino Biotechnology (Primary) ; AZD 1222 (Primary) ; BBIBP CorV (Primary) ; BBV 152 (Primary) ; COVID-19 vaccine adjuvanted Novavax (Primary) ; COVID-19 vaccine-Gamaleya National Research Center of Epidemiology and Microbiology (Primary) ; Elasomeran (Primary) ; SARS-COV-2 vaccine-inactivated-Sinovac-Biotech (Primary) ; Tozinameran (Primary)
Indications COVID 2019 infections
Focus Therapeutic Use

27 Sep 2022 New trial record
28 Aug 2022 Results (as of 31 Dec 2021) presented at the 38th International Conference on Pharmacoepidemiology and Therapeutic Risk Management

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com